Polymerase epsilon exonuclease domain mutations in ovarian endometrioid carcinoma

International Journal of Gynecological Cancer

Volumn 25, Issue 7, 2015, Pages 1187-1193

  Hoang, Lien N ^a,b   McConechy, Melissa K ^a,b   Köbel, Martin ^c,d   Anglesio, Michael ^a,b   Senz, Janine ^a,b   Maassen, Malden ^e   Kommoss, Stefan ^e   Meng, Bo ^f,g   Postovit, Lynne ^g   Kelemen, Linda E ^h,i   Staebler, Annette ^e   Brucker, Sara ^e   Krämer, Bernhard ^e   McAlpine, Jessica N ^b   Gilks, C Blake ^a,b   Huntsman, David G ^a,b   Lee, Cheng Han ^f,g  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c CALGARY LABORATORY SERVICES   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f UNIVERSITY OF ALBERTA   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Endometrioid carcinoma; Ovarian carcinoma; POLE; Polymerase epsilon; TCGA

Indexed keywords

DNA POLYMERASE; EXONUCLEASE; POLYMERASE EPSILON EXONUCLEASE; UNCLASSIFIED DRUG; DNA DIRECTED DNA POLYMERASE ALPHA; POLE PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE COURSE; ENDOMETRIOID CARCINOMA; ENDOMETRIOID CARCINOMAS OF THE OVARY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; MISSENSE MUTATION; OVARY CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; RECURRENT DISEASE; SOMATIC MUTATION; CANCER GRADING; CANCER STAGING; ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; ENZYMOLOGY; FOLLOW UP; GENETICS; MORTALITY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; PROTEIN TERTIARY STRUCTURE; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DNA POLYMERASE II; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; POINT MUTATION; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; SURVIVAL RATE;

EID: 84940941781     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000492     Document Type: Article

References (27)

1. Heitzer E, Tomlinson I. Replicative DNA polymerase mutations in cancer. Curr Opin Genet Dev. 2001;24:107-113.
2. Loeb LA, Monnat RJ. DNA polymeras es and human disease. Nat Rev Genet. 2008;9:594-604.
3. Kane DP, Shcherbakova PV. A common cancer-Associated DNA polymerase ? mutation causes an exceptionally strong mutator phenotype, indicating fidelit y defects distinct from loss of proofreading. Cancer Res. 2014;74:1895-1901.
4. Agbor AA, Göksenin AY, LeCompte KG, et al. Human Pol ?-dependent replication errors and the influence of mismatch repair on their correction. DNA Repair. 2013;12:954-963.
5. Albertson TM, Ogawa M, Bugni JM, et al. DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice. Proc Natl Acad Sci U S A. 2009;106:17101-17104.
6. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.
7. Cancer Genome Atlas Net work. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330-337.
8. Briggs S, Tomlinson I. Germline and somatic polymerase D and C mutations define a new class of hypermutated colorectal and endometrial cancers. J Pathol. 2013;230:148-153.
9. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150:1121-1134.
10. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463:191-196.
11. Rohlin A, Zagoras T, Nilsson S, et al. A mutation in POLE predisposing to a multi-tumour phenotype. Int J Oncol. 2014;45:77-81.
12. Church DN, Briggs SE, Palles C, et al. DNA polymerase ? and C exonuclease domain mutations in endometrial cancer. Hum Mol Genet. 2013;22:2820-2828.
13. Billingsley CC, Cohn DE, Mutch DG, et al. Polymerase ? (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer. 2014;121:386-394.
14. Hoang LN, McConechy MK, Meng B, et al. Targeted mutation analysis of endometrial clear cell carcinoma. Histopathology. 2015;66:664-674.
15. Meng B, Hoa ng LN, McIntyre JB, et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol. 2014;134:15-19.
16. Hussein Y R, Weigelt B, Levine DA, et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol. 2015;28:505-514.
17. Zou Y, Liu FY, Liu H, et al. Frequent POLE1 p.S297F mutation in Chinese patients with ovarian endometrioid carcinoma. Mutat Res. 2014;761:49-52.
18. Soliman PT, Slomovitz BM, Broaddus RR, et al. Syn chronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004;94:456-462.
19. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43:420-432.
20. Kurman RJ,Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancerVshifting the paradigm Hum Pathol. 2011, 42, 918-931
21. Geyer JT, Lopez-Garcia MA, Sanchez-Estevez C, et al. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol. 2009;33: 1157-1163.
22. Jiang X, Morland SJ, Hitchcock A, et al. Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res. 1998;58:1707-1712.
23. McConechy MK, Ding J, Senz J, et al. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 2014;27:128-134.
24. Yamaguchi K, Mandai M, Toyokuni S, et al. Contents of endometriotic cysts, especially the high concentration of free ir on, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res. 2008;14:32-40.
25. McConechy MK, Anglesio MS, Kalloger SE, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol. 2011;223:567-573.
26. Catasús L, Bussaglia E, Rodrguez I, et al. Molecular genetic alterations in endometrioi d carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol. 2004;35: 1360-1368.
27. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474: 609-615.